Fibrinogen disorders: too little, faulty or used up
- Look-alikes compared
Fibrinogen is the raw material of a clot. Missing, faulty or used-up fibrinogen causes bleeding, and, oddly, some faulty forms cause clots instead.
What it is
Fibrinogen, made in the liver, is cut by thrombin into fibrin, the mesh that holds a clot together. Inherited disorders are quantitative (afibrinogenaemia: essentially none; hypofibrinogenaemia: too little but normal in quality) or qualitative (dysfibrinogenaemia: a normal amount that works poorly; hypodysfibrinogenaemia: too little and faulty). Acquired low fibrinogen is far commoner and comes from consumption (DIC, thrombolysis), dilution and loss (massive bleeding and transfusion), or poor production (severe liver disease, asparaginase). Telling them apart rests on two numbers: how well fibrinogen clots (Clauss activity) and how much protein is there (antigen).
The difference in one line
- Afibrinogenaemia is autosomal recessive (FGA, FGB or FGG) and very rare, about 1 to 2 per million; hypofibrinogenaemia is usually the heterozygous state of the same mutations.
- Dysfibrinogenaemia is mostly autosomal dominant; about 55% of patients have no symptoms, 25% bleed and 20% have thrombosis.
- Activity-to-antigen ratio: above about 0.7 fits hypofibrinogenaemia; below about 0.7 fits dysfibrinogenaemia or hypodysfibrinogenaemia.
- Thrombosis is a real paradox: it is reported in about one in five patients with a congenital fibrinogen disorder, afibrinogenaemia included.
- Fibrinogen is needed for the placenta to attach and grow, so inherited deficiency brings recurrent early miscarriage, abruption and postpartum bleeding.
- Acquired: haemodilution and consumption are the commonest causes; thrombolysis lowers fibrinogen on purpose; asparaginase lowers both fibrinogen and antithrombin, so clots as well as bleeding are a risk.
Absent, scarce, faulty or used up
| Feature | Afibrinogenaemia | Hypofibrinogenaemia | Dysfibrinogenaemia (and hypodys-) | Acquired low fibrinogen |
|---|---|---|---|---|
| What is wrong | No fibrinogen made | Too little, normal quality | Normal (or low) amount that clots poorly | Used up, diluted or not made (DIC, thrombolysis, massive transfusion, liver, asparaginase) |
| Inheritance | Autosomal recessive | Usually one faulty copy (dominant) | Mostly autosomal dominant | None: follows the illness or drug |
| Clauss activity vs antigen | Both unmeasurable | Both low; ratio above about 0.7 | Activity much lower than antigen; ratio below about 0.7 | Both low; check the trend |
| Thrombin time and reptilase time | Both very prolonged | Prolonged in proportion to the level | Prolonged (both) | Prolonged; thrombin time also long with heparin or breakdown products |
| PT and aPTT | Very prolonged (unclottable) | Normal or mildly long | Often near normal | Long in DIC, liver disease and dilution |
| Typical picture | Umbilical stump bleeding, joint and muscle bleeds, brain bleeds, splenic rupture | Often mild; bleeding after surgery, delivery or injury | Often a chance lab finding; bleeding, thrombosis or both | Bleeding in the setting of the cause |
| Treatment in principle | Fibrinogen concentrate for bleeds and surgery; prophylaxis after severe bleeds | Replace before surgery or delivery if low or bleeding | Guided by personal and family history: observe, replace, or give thromboprophylaxis | Treat the cause; replace fibrinogen when bleeding with a low level |
In clinical practice
- A newborn whose umbilical stump keeps oozing, with an unclottable PT and aPTT, should have fibrinogen measured at once; this is the first sign in most children with afibrinogenaemia.
- A healthy adult with a low Clauss fibrinogen on a pre-operative screen and no bleeding history is the classic dysfibrinogenaemia story: measure antigen before treating a number.
- Women with an inherited fibrinogen disorder need a haematology and obstetric plan before pregnancy because of miscarriage, abruption and postpartum haemorrhage.
- In a bleeding patient with DIC, massive transfusion or after thrombolysis, falling fibrinogen is an early, treatable cause of ongoing bleeding.
- Children receiving asparaginase for leukaemia have fibrinogen and antithrombin checked: a low fibrinogen here marks clotting risk as much as bleeding risk.
How it is confirmed
- Start with PT, aPTT, thrombin time and Clauss fibrinogen; if Clauss is low, measure fibrinogen antigen and work out the activity-to-antigen ratio.
- Long thrombin time with a normal reptilase time points to heparin in the sample; both long points to a fibrinogen problem.
- Do not trust a PT-derived fibrinogen to rule out a problem: it reads higher than Clauss and can look normal in dysfibrinogenaemia.
- Confirm an inherited disorder with family testing and FGA, FGB and FGG genetic testing; dysfibrinogenaemia usually shows the same pattern in a parent.
- Treatment in principle: fibrinogen concentrate is preferred; cryoprecipitate or plasma only if it is unavailable; tranexamic acid for mucosal bleeding, used with care after a thrombosis; anticoagulation may be needed alongside replacement in those who clot.
Common traps
- Reading a low Clauss fibrinogen as too little fibrinogen: Clauss measures function, so dysfibrinogenaemia gives the same result; the antigen tells them apart.
- Assuming no fibrinogen means no clots: thrombosis occurs in about one in five congenital cases, afibrinogenaemia included, because free thrombin and lysis-resistant fibrin persist.
- Treating every dysfibrinogenaemia with replacement: most patients never bleed, and replacement can tip a clot-prone patient into thrombosis; history guides treatment.
- Calling a normal fibrinogen reassuring in sepsis or pregnancy: it is an acute-phase protein, so a normal value can already be a steep fall.
- Giving cryoprecipitate as first choice: it also carries factor VIII and von Willebrand factor and is less purified; concentrate is preferred when available.
Test yourself
Think of the answer, then tap the question to see it.
A 30-year-old with no bleeding history has a low Clauss fibrinogen before surgery and a prolonged thrombin time. What is the next test, and what result would suggest dysfibrinogenaemia?
Fibrinogen antigen: a normal or near-normal antigen with a much lower activity (ratio below about 0.7) suggests dysfibrinogenaemia rather than true hypofibrinogenaemia.
Why can a person with almost no fibrinogen still develop thrombosis?
Fibrin normally binds and holds thrombin; without it thrombin stays free and generation rises, and replacement, surgery or pregnancy add risk.
Thrombin time is long but reptilase time is normal. What is the likely cause?
Heparin in the sample: heparin blocks thrombin but not the snake-venom enzyme used in the reptilase time.
Why do women with congenital afibrinogenaemia often miscarry early without treatment?
Fibrinogen is needed for trophoblast attachment and the growth of the maternal-fetal circulation, so the placenta fails without it.
Elsewhere in DurgiPedia
- The coagulation cascade
- Coagulation tests: PT/INR, aPTT and platelets
- Fibrinolysis and natural anticoagulants
- Acquired coagulation factor disorders
- Coagulation tests: PT/INR, aPTT, fibrinogen and D-dimer
Connections
In Pharmacology4
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Congenital afibrinogenemia: MedlinePlus Genetics (MedlinePlus Genetics, US National Library of Medicine, 2014); FGA gene: MedlinePlus Genetics (MedlinePlus Genetics, US National Library of Medicine, 2012); Congenital afibrinogenemia and hypofibrinogenemia: laboratory and genetic testing in rare bleeding disorders with life-threatening clinical manifestations and challenging management (Diagnostics (Basel), PMC open access, 2021); The thrombotic paradox in congenital fibrinogen deficiencies: from pathophysiology to practice (Research and Practice in Thrombosis and Haemostasis, PMC open access, 2025); Acquired hypofibrinogenemia: current perspectives (Journal of Blood Medicine, PMC open access, 2016); Treatment of congenital fibrinogen deficiency: overview and recent findings (Vascular Health and Risk Management, PMC open access, 2009); Misdiagnosis of a patient with congenital dysfibrinogenemia: a case report and literature review (Journal of Clinical Laboratory Analysis, PMC open access, 2022); Women with congenital hypofibrinogenemia/afibrinogenemia: from birth to death (Clinical and Applied Thrombosis/Hemostasis, PMC open access, 2020).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
